Cargando…
Complete remission of Hodgkin’s lymphoma in a pediatric patient with TTN gene mutation treated with brentuximab vedotin combined chemotherapy without anthracyclines: A case report
INTRODUCTION: There is no guideline for the treatment of Hodgkin’s lymphoma (HL) in pediatric patients with titin (TTN) gene mutation and heart failure. We explored the feasibility of using brentuximab vedotin (BV) plus chemotherapy without anthracyclines to treat one pediatric HL patient with TTN m...
Autores principales: | Li, Ying, Liu, Ligang, Sun, Hao, Li, Nan, Huang, Shuang, Olinger, Alexander, Xu, Xiaolin, Wang, Xiaoling, Duan, Yanlong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618631/ https://www.ncbi.nlm.nih.gov/pubmed/36324585 http://dx.doi.org/10.3389/fonc.2022.1006166 |
Ejemplares similares
-
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013) -
Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018) -
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019) -
Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012)